Wu, Junlong
Lin, Yuda
Yang, Kaiwei
Liu, Xiao
Wang, Huina
Yu, Tingting
Tao, Ran
Guo, Jing
Chen, Libin
Cheng, Huanqing
Lou, Feng
Cao, Shanbo
Yu, Wei
Hu, Hailong
Ye, Dingwei
Funding for this research was provided by:
Tianjin Municipal Health Industry Key Project (TJWJ2022XK014)
Scientific Research Project of Tianjin Municipal Education Commission (2022ZD069)
Tianjin Institute of Urology Talent Funding Program (MYSRC202310)
Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-023A)
Zhaoyang Cancer Research Fund of The Chinese Society of Clinical Oncology (Y-Young2023-0087)
Shanghai Municipal Health Bureau Project (2020CXJQ03)
Article History
Received: 26 October 2023
Accepted: 28 February 2024
First Online: 19 March 2024
Declarations
:
: The study was conducted in accordance with the ethical principles in the Declaration of Helsinki and was approved by the Institutional Review Board of Fudan University Shanghai Cancer Center (No. 2210263-17), The Second Affiliated Hospital of Tianjin Medical University (No. 2022-049), and Peking University First Hospital (No. 2022130-002). Written informed consent was obtained from all participants.
: Not applicable.
: X.L., H.W., T.Y., R.T., J.G., L.C., H.C., F.L., and S.C. are current employees of Acornmed Biotechnology Co., Ltd. The remaining authors declare that they have no competing interests.